<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01242020</url>
  </required_header>
  <id_info>
    <org_study_id>811310</org_study_id>
    <nct_id>NCT01242020</nct_id>
  </id_info>
  <brief_title>Microvascular Flow Assessment Repeatability Study: The MARS Study</brief_title>
  <acronym>MARS</acronym>
  <official_title>Microvascular Flow Assessment of the Periadventitial Adipose Tissue, Subcutaneous Adipose Tissue and Skeletal Muscle Using Contrast Enhanced Ultrasound (CEU); A Repeatability Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test a method of imaging (taking a picture) of the abdomen
      (belly), neck, thigh and calf (lower leg) areas of the body, using ultrasound along with a
      drug which makes the pictures look clearer. Ultrasound is a type of imaging that uses sound
      waves to create a picture of the inside of the human body. Two sets of pictures will be taken
      on two different days to see if the results are the same each time.

      DEFINITY® is a drug given intravenously (through the vein). DEFINITY® is approved by the FDA
      to be used as an ultrasound contrast agent (makes the pictures look clearer) while taking
      pictures of the heart. In this study, DEFINITY® will be used while taking pictures of blood
      vessels in your abdomen (belly), neck, thigh and calf (lower leg). Since this use of
      DEFINITY® is different than the use approved by the FDA, this study will be performed under
      an FDA Investigational New Drug (IND) application.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to reliably reproduce, visualize, or quantify microvascular flow in the subcutaneous
    tissue, the skeletal muscle or peri-adventitia
  </why_stopped>
  <start_date type="Actual">January 2011</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variability of Repeated Measures for Each Subject</measure>
    <time_frame>up to 30 days</time_frame>
    <description>The variability of repeated measures for each subject, expressed as coefficient of variation (CV), in the periadventitial microvascular flow, subcutaneous microvascular flow and skeletal muscle flow.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microvascular Flow in the Periadventitial, Subcutaneous and Skeletal Muscle Tissues</measure>
    <time_frame>up to 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Lean Healthy Subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>&quot;Lean&quot; defined as (BMI ≥18 and ≤25)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese Healthy Subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Obese grade I-II defined as (BMI&gt;30 and ≤35)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perflutren Lipid Microsphere Injectable Suspension</intervention_name>
    <description>1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used</description>
    <arm_group_label>Lean Healthy Subjects</arm_group_label>
    <arm_group_label>Obese Healthy Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and non-pregnant/lactating women between the ages of 18 and 45;

          2. Lean (BMI ≥18 and ≤25) or Obese grade I-II(BMI&gt;30 and ≤35)

          3. Provide written informed consent and sign HIPAA Waiver of Authorization

          4. Be able and willing to follow all instructions and attend all study visits

        Exclusion Criteria:

        Subjects must not have been diagnosed with:

          1. Coronary artery disease

          2. Congestive heart failure

          3. Congenital heart disease (Right-to-left, bi-directional, or transient right-to-left
             cardiac shunts)

          4. Hypersensitivity to perflutren

          5. Renal disease

          6. Chronic obstructive pulmonary disease or Asthma

          7. Primary or secondary pulmonary hypertension

          8. Obstructive sleep apnea

          9. Thyroid disease

         10. Vasculitis

         11. Peripheral arterial disease.

         12. Cancer

         13. Any type of immunosuppression

         14. Any active infection (systemic or of the underlying skin or subcutaneous tissue).

         15. Taking any prescribed medication for hypertension, dyslipidemia or diabetes.

         16. Current or past smoking in the last 12 months.

         17. Positive urine pregnancy test

         18. Creatinine (Cr) above 1.4 mg/dl on screening evaluation

         19. Hemoglobin (Hb) less than 10 mg/dl on screening evaluation

         20. Aspartate Transaminase (AST) or Alanine Transaminase (ALT) two fold above upper limit
             of normal on screening evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muredach P Reilly, MB, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis H. Eraso, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical and Translational Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2010</study_first_submitted>
  <study_first_submitted_qc>November 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2010</study_first_posted>
  <results_first_submitted>July 13, 2017</results_first_submitted>
  <results_first_submitted_qc>July 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 10, 2017</results_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lean Healthy Subjects</title>
          <description>&quot;Lean&quot; defined as (BMI ≥18 and ≤25)
Perflutren Lipid Microsphere Injectable Suspension: 1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used</description>
        </group>
        <group group_id="P2">
          <title>Obese Healthy Subjects</title>
          <description>Obese grade I-II defined as (BMI&gt;30 and ≤35)
Perflutren Lipid Microsphere Injectable Suspension: 1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed screening</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lean Healthy Subjects</title>
          <description>&quot;Lean&quot; defined as (BMI ≥18 and ≤25)
Perflutren Lipid Microsphere Injectable Suspension: 1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used</description>
        </group>
        <group group_id="B2">
          <title>Obese Healthy Subjects</title>
          <description>Obese grade I-II defined as (BMI&gt;30 and ≤35)
Perflutren Lipid Microsphere Injectable Suspension: 1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Variability of Repeated Measures for Each Subject</title>
        <description>The variability of repeated measures for each subject, expressed as coefficient of variation (CV), in the periadventitial microvascular flow, subcutaneous microvascular flow and skeletal muscle flow.</description>
        <time_frame>up to 30 days</time_frame>
        <population>Reliable data for periadventitial microvascular flow, subcutaneous microvascular flow, and skeletal microvascular flow were not collected for the Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lean Healthy Subjects</title>
            <description>&quot;Lean&quot; defined as (BMI ≥18 and ≤25)
Perflutren Lipid Microsphere Injectable Suspension: 1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used</description>
          </group>
          <group group_id="O2">
            <title>Obese Healthy Subjects</title>
            <description>Obese grade I-II defined as (BMI&gt;30 and ≤35)
Perflutren Lipid Microsphere Injectable Suspension: 1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used</description>
          </group>
        </group_list>
        <measure>
          <title>Variability of Repeated Measures for Each Subject</title>
          <description>The variability of repeated measures for each subject, expressed as coefficient of variation (CV), in the periadventitial microvascular flow, subcutaneous microvascular flow and skeletal muscle flow.</description>
          <population>Reliable data for periadventitial microvascular flow, subcutaneous microvascular flow, and skeletal microvascular flow were not collected for the Outcome Measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microvascular Flow in the Periadventitial, Subcutaneous and Skeletal Muscle Tissues</title>
        <time_frame>up to 30 days</time_frame>
        <population>Reliable data for periadventitial microvascular flow, subcutaneous microvascular flow, and skeletal muscle microvascular flow were not be collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Lean Healthy Subjects</title>
            <description>&quot;Lean&quot; defined as (BMI ≥18 and ≤25)
Perflutren Lipid Microsphere Injectable Suspension: 1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used</description>
          </group>
          <group group_id="O2">
            <title>Obese Healthy Subjects</title>
            <description>Obese grade I-II defined as (BMI&gt;30 and ≤35)
Perflutren Lipid Microsphere Injectable Suspension: 1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used</description>
          </group>
        </group_list>
        <measure>
          <title>Microvascular Flow in the Periadventitial, Subcutaneous and Skeletal Muscle Tissues</title>
          <population>Reliable data for periadventitial microvascular flow, subcutaneous microvascular flow, and skeletal muscle microvascular flow were not be collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lean Healthy Subjects</title>
          <description>&quot;Lean&quot; defined as (BMI ≥18 and ≤25)
Perflutren Lipid Microsphere Injectable Suspension: 1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used</description>
        </group>
        <group group_id="E2">
          <title>Obese Healthy Subjects</title>
          <description>Obese grade I-II defined as (BMI&gt;30 and ≤35)
Perflutren Lipid Microsphere Injectable Suspension: 1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination (not feasible with available equipment) leading to small number of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Muredach P. Reilly, MBBCh, MSCE</name_or_title>
      <organization>Associate Dean for Clinical and Translational Research, College of Physicians and Surgeons</organization>
      <phone>212-305-9453</phone>
      <email>mpr2144@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

